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tracing diagnosis trajectories 
over millions of patients reveal an 
unexpected risk in schizophrenia
Hyojung Paik1,2,3,4, Matthew J. Kan1,2, Nadav Rappoport  1,2, Dexter Hadley1,2, 
Marina Sirota1,2, Bin Chen1,2, Udi Manber1,5, Seong Beom Cho4 & Atul J. Butte  1,2
The identification of novel disease associations using big-data for patient care has had limited success. 
In this study, we created a longitudinal disease network of traced readmissions (disease trajectories), 
merging data from over 10.4 million inpatients through the Healthcare Cost and Utilization 
Project, which allowed the representation of disease progression mapping over 300 diseases. From 
these disease trajectories, we discovered an interesting association between schizophrenia and 
rhabdomyolysis, a rare muscle disease (incidence < 1E-04) (relative risk, 2.21 [1.80–2.71, confidence 
interval = 0.95], P-value 9.54E-15). We validated this association by using independent electronic 
medical records from over 830,000 patients at the University of California, San Francisco (UCSF) medical 
center. A case review of 29 rhabdomyolysis incidents in schizophrenia patients at UCSF demonstrated 
that 62% are idiopathic, without the use of any drug known to lead to this adverse event, suggesting a 
warning to physicians to watch for this unexpected risk of schizophrenia. Large-scale analysis of disease 
trajectories can help physicians understand potential sequential events in their patients.
Introduction
One of the most basic aspects of clinical care in hospitals is understanding disease and mortality risk factors, 
particularly for rare but preventable diseases or outcomes1–3. Although mapping disease relationships has a long 
history, the recent advent of digitalized health records and disease registries has led to an enhanced ability to 
organize and analyze healthcare data. The availability of these data allows the recapitulation of known temporal 
disease correlations using nonlongitudinal data4, exploration of unordered disease pairs5,6, and enables network 
analyses of disease relationships at a national scale7. However, while big-data analytics have aided the ability to 
visualize, search, and organize health data8,9, there has been limited success in identifying and validating novel 
temporal relationships between diseases that would meaningfully change clinical care.
Here, we showcase a novel temporal disease association that was discovered in the course of a large-scale 
analysis of California inpatient hospitalizations using data from the Healthcare Cost and Utilization Project 
(HCUP)10. By using the California State Inpatient Database (CA SID) from HCUP, we analyzed longitudinal 
inpatient discharge data collected between 1980 and 2010 from 350 California hospitals, representing 10.4 million 
ethnically diverse individuals. Based on inpatient diagnoses, we identified temporal correlations between disease 
pairs7 and concatenated these correlations to create a network-based representation of disease trajectories from 
initial hospitalization until death in a hospital. By using a combination of computational analysis and healthcare 
expert curation, an unexpected relationship between inpatient admissions for schizophrenia, a psychiatric disor-
der, and readmission for rhabdomyolysis was discovered.
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Rhabdomyolysis is a rare disease of muscle breakdown that can lead to severe outcomes for patients, including 
kidney failure11. We validated this finding by performing a case review of patients treated for schizophrenia and 
rhabdomyolysis at the Medical Center of the University of California, San Francisco (UCSF), thereby demonstrat-
ing the reproducibility of the identified association between schizophrenia and rhabdomyolysis. Multifactorial 
origins of rhabdomyolysis, such as adverse effects of drugs, catatonic stupor, neuroleptic malignant syndrome 
(NMS), and trauma12–14, have been reported. Our analytics highlighted an unexpected and idiopathic risk of 
rhabdomyolysis in schizophrenia patients.
Together, these findings demonstrate the power of using multi-level medical records, including public disease 
registries in combination with detailed electronic medical records, to discover novel disease associations, explore 
their etiologies, and inform clinical practice.
Results
Data set and overview of analytics. As a main study set, we used the five editions of the annually released 
HCUP datasets from the CA SID, which contains inpatient billing records organized by the Agency for Healthcare 
Research and Quality (AHRQ) (https://www.hcup-us.ahrq.gov), including International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and death outcomes in hospitals, collected 
from over 350 community hospitals in California. The CA SID uses unique patient identifiers for each edition; 
thus, discharge data within the years is kept together for each patient within each edition, such as between 1980 
and 2010 in the 2010 edition, but cannot be linked across previous editions. Therefore, while each edition of 
CA SID covers the longitudinal history of inpatient records for each patient across over 20 years (Fig. 1a), the 
patient record cannot be mapped between different editions of CA SID. To prevent recounting the same patients, 
we started with the 2010 data edition and then added record data from previous editions only for patients that 
were deceased during that year (and thus, could not have been admitted again in the 2010 edition) (see Methods 
and Fig. 1a, Supplementary Fig. S1A). The patients may have been treated for multiple illnesses during a hospi-
talization, both acute and chronic, so the first assigned diagnosis was used as the principal diagnosis for each 
admission. Given that we were interested in tracing the relationships of diseases, we filtered out ICD codes for 
non-disease conditions, which we defined as diagnosis chapters from ICD-9-CM, referring to injury, pregnancy, 
external causes, and healthcare-related administration codes. The merged data set covered 2,272,018 hospitaliza-
tions for 1,488,551 individuals with 290,253 death outcomes. The mean age of patients in the merged CA SID was 
63.77 ± 19.58 years. (Supplementary Table S1).
As we were interested in temporal relationships between disease diagnoses within individuals, we simplified 
the timeline of each patient to the first instance of each primary diagnosis, such that readmissions for the same 
disease were removed. All diagnosis codes were reported using the ICD-9-CM and rounded to the three-digit 
code level15 to minimize overlap and subclassification of diagnoses (see Methods). Based on the intervals between 
the first and last admission dates for each individual, most of the merged CA SID data included diagnostic time-
lines for each patient of over three years (the median interval between the first and last admission dates per patient 
was 40.58 ± 2.5 months, see Supplementary Fig. S1C). The longest duration between the first and most recent 
admission dates in a patient was 26 years. We then identified significant disease associations by establishing the 
relative association (RA) of diagnoses co-occurring within one year in a patient4,6 using a binomial test, and com-
pensating for multiple hypothesis testing using a false discovery rate (FDR) < 0.1 (see Methods)7. In short, RA is 
a ratio of the actual probability of co-diagnoses of two diseases over the random expectation of co-occurrences. 
When RA is greater than 1, it indicates the observed disease co-occurrence is higher than expected by chance (the 
details are shown in the Methods). We chose an interval of one year because the majority of new admissions of 
patients occurred within the same year, and we assumed admissions separated by very long-term intervals were 
less likely to be related.
Of the 691 three-digit level ICD-9-CM diagnosis codes used in the merged data set, 168 disease diagnoses 
were associated with at least one of the other 167 diseases, with a total of 300 temporally aligned disease pairs at 
FDR < 0.1. We determined the average time direction within each pair to determine the temporal relationship 
between diagnoses. Given that our data (CA SID) represent a statewide inpatient data set, the initial date of dis-
ease diagnosis is based on the date of admission for a disease. By using a greedy search algorithm7 (i.e., traced 
temporal relationships between diagnoses with the largest number of patients), we then concatenated these 300 
temporal parings to create larger directed acyclic graphs (DAGs). By iterating over each starting disease compiled 
DAG, we retrospectively mapped 300 common trajectories from initial hospitalization through intermediate hos-
pitalizations until death, if applicable (Fig. 1b). The 300 presented DAGs have 118 different diseases as nodes for 
the first diagnosis. The associated admissions cover 311,309 patients, who had 175,556 recorded readmissions for 
distinct diseases that are statistically correlated and that are presented as edges between disease diagnosis nodes. 
Of the traced patients, 34% (59,794) reached fatal outcomes as hospital inpatients.
DAGs depict temporal disease associations and mortality. In total, we identified 300 major trajecto-
ries (i.e., DAGs) consisting of nodes for disease diagnoses, and edges for subsequent readmission for statistically 
associated disease diagnoses. Of the 300 trajectories, the longest trajectory had four readmission steps for corre-
lated diseases from the initial presentation of disease diagnosis. In 257 trajectories, the latest steps of readmissions 
are associated with fatal outcomes, i.e., deaths in the care setting. In 43 cases, the traced patients were either still 
alive or there were no death outcomes at the final disease diagnosed (Supplementary Fig. S1D). While the data-
set is too comprehensive to review all our findings in detail (see Appendix Movie S1. Dynamic presentation of 
the traced diagnosis trajectories at scale; https://www.youtube.com/watch?v=jJMds31-e2g), we highlight a few 
selected trajectories (i.e., DAGs).
We focused on three DAGs within the network that represent the disease trajectories leading to the most 
hospital deaths in California (Fig. 2). Among patients in their fifties, most hospital deaths (2,237 deaths) occurred 
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within the DAG associated with a “chronic liver disease and cirrhosis,” which was the initial presentation of 
disease in the DAG for 5,416 patients. A significant portion (up to 35%) experienced infection complications 
(liver abscess and sequelae of chronic liver disease)16 and then sepsis, with most deaths associated with these ICD 
diagnoses (Fig. 2a). We also recapitulated a well-known phenomenon that acute myocardial infarction commonly 
leads to heart failure17 and that these steps of diseases have high mortality (19%; 2,245 deaths among 11,624 of the 
traced acute myocardial infarction patients) (Fig. 2b). Thus, identified diagnosis patterns within DAGs appeared 
to be reliable and represent currently understood phenomena.
We also present the DAG for pneumonia, which disproportionately affects older individuals (mean age in 
the 70 s). This DAG demonstrated a network with both high morbidity and mortality. Associated subsequent 
diagnoses included heart failure and subsequent lung disease3, aspiration pneumonia (pneumonitis due to solids 
and liquids), and sepsis (Fig. 2c). Indeed, sepsis was a common dead-end node in many DAGs, which reinforces 
previous studies demonstrating the high prevalence of sepsis in the USA18. Together, these findings allow com-
mon disease paths to be traced and enables diseases of high mortality in clinics to be identified in a systematic 
fashion. In addition to recapitulating identified disease trajectories, greater detail of 300 trajectories (i.e., DAGs) 
are presented in the appendix data of traced diagnosis trajectories (https://github.com/hypaik/HCUPSIDCA_
trajectory_tracking). Moreover, details of all modeled trajectories, which are described in Appendix Data 
S1, might be helpful to understand the heterogeneity of patients for clinical care (https://github.com/hypaik/
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Fig. 1 Overview of the main study data and analytics. (a) Overview of the data set build and analytics. We 
prepared the study data set by combining five editions of the California State Inpatient Database (CA SID) sets, 
which were released annually (2006–2010). In summary, we removed admissions for which primary diagnoses 
were not related to disease (pregnancy, injury, external causes, administration). The merged CA SID covers 
longitudinal records (1980–2010) for >1.4 million patients without data redundancy. (b) Construction of 
DAGs. The principal inpatient diagnoses for patients were selected and 682 significant disease association pairs 
(RA > 1, FDR < 0.1) were identified. The average temporal correlation was determined within pairs and then 
concatenated by using a greedy algorithm to create DAGs (i.e., trajectories) with 117 starting nodes.
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Fig. 2 Selected disease trajectories (DAGs). Selected DAGs (117 in total) showing trajectories for one-year 
intervals between primary diagnosis codes for California inpatient admissions. Areas of shapes are directly 
proportional to the number of patients, where circles represent primary diagnoses and squares represent deaths. 
Nodes are colored by mean age of patients. The thickness of edges is determined by the number of patients 
traveling along the edge (see Legend). (a) DAG of “chronic liver disease and cirrhosis.” Prominent nodes include 
“liver abscess and sequelae of chronic liver disease,” “septicemia,” and “death.” (b) DAG of “acute myocardial 
infarction.” The majority of readmissions were for “heart failure” and “other forms of chronic ischemic heart 
disease,” and “acute myocardial infarction” and “heart failure” were the nodes most associated with death. Note 
that some of these second diagnoses occur in a larger population of patients beyond those coming in with 
acute myocardial infarction, and this can lower their mean age of incidence. (c) DAG of “pneumonia, organism 
NOS.” Common readmissions were for “septicemia,” “heart failure,” “other disease of lung,” “pneumonitis due 
to solids and liquids,” and “other bacterial pneumonia.” These diagnoses were all strongly associated with death. 
(d) DAG of “episodic mood disorders,” which includes diagnosis codes for uncharacterized mental disorders. 
The majority of hospitalizations were readmitted for diagnoses of “schizophrenia” and a significant proportion 
of these individuals were later hospitalized for “disorders of muscle ligament and fascia;” 93% of the admissions 
for “disorders of muscle ligament and fascia” were more specifically coded for rhabdomyolysis (ICD-9-CM 
code = 728.88).
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HCUPSIDCA_trajectory_tracking). For example, osteomyelitis periostitis patients (i.e., inflammation of bone, 
ICD-9 code: 730) were stratified based on the correlated previous diagnoses, cellulitis, and diabetes.
Schizophrenia is associated with subsequent hospitalization for rhabdomyolysis. We also 
found a surprising relationship between schizophrenia and muscle disorders (Fig. 2d). In this DAG, 4,822 patients 
were first diagnosed with episodic mood disorders, which are often used in initial diagnoses for psychiatric dis-
eases while medical providers collect collateral data to make a more specific clinical diagnosis. As expected, 
76% (3,674) were subsequently readmitted with schizophrenia (schizophrenic disorders). While diagnoses for 
psychotic disorders exist on a continuum of clinical symptoms, the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V) requires either two outpatient evaluations or one inpatient hospitalization 
to make a diagnosis for schizophrenia. Therefore, we felt confident in this categorization. Interestingly, 98 of the 
3,674 patients (2.6%) with schizophrenia were readmitted within one year with muscle disorders. Of these 98 
patients with disorders of muscle, ligament, and fascia, 92 (2.5% of 3,674 schizophrenia patients) were more spe-
cifically coded as having rhabdomyolysis, which is usually a rare disease of muscle breakdown that can lead to kid-
ney failure or even death (relative risk of rhabdomyolysis [RR] = 2.21 [1.80–2.71, confidence interval (CI) = 0.95] 
P-value of RR 9.54E-15, RA = 1.5, mean interval 114.9 ± 84.3 days, FDR of RA and temporal order = 8.76E-02) 
(Fig. 3a). Although it has been historically very difficult to study the epidemiology of rhabdomyolysis, an inci-
dence of lower than 0.0001 (26,000/year among the 325 million US population, or an incidence of 8E-05 per year) 
has been estimated19. Thus, a rate of 2.5% in a specific patient population (schizophrenia) was peculiarly high 
(313-fold higher than a population-wide incidence of rhabdomyolysis; 0.026 is 325 times greater than 8E-05) 
(P-value of enrichment using hypergeometric test 7.20E-03). There has been one case report describing the use of 
second-generation antipsychotics, such as aripiprazole20 (a schizophrenia drug for adolescent patients21), being 
associated with rhabdomyolysis in a schizophrenia patient. Regarding the rare and immediate adverse effect 
of aripiprazole, the association with schizophrenia is not a widely known disease association (calculated mean 
interval between schizophrenia and rhabdomyolysis = 114.9 ± 84.3 days). Thus, we sought to verify and further 
characterize this novel relationship.
Multi-level validation of patients with schizophrenia diagnosed with rhabdomyolysis. To bet-
ter understand the potential etiology of rhabdomyolysis in schizophrenia patients, we searched for this relation-
ship using deidentified electronic health records (EHRs) from the UCSF Medical Center. While UCSF is one of 
the contributors to the CA SID, the UCSF EHR data we used consisted of inpatient and outpatient encounters 
from 836,461 patients between 2011–2018 (inpatients = 123,752 patients), whereas the merged CA SID we used 
consisted of five editions of CA SIDs covering inpatients between 1980 and 2010. In addition, the CA SID data 
covers nearly 69 times the number of discharges compared with UCSF. Thus, we believe the data in the UCSF and 
CA SID do not overlap, and if they do, the overlap is minimal; however given that both datasets are deidentified, 
we were not able to verify this. We began by using UCSF’s deidentified EHR Clinical Data Warehouse, which 
contains structured data including diagnosis codes, lab values, vital signs, procedure codes, and administered 
medications, without any clinical text, images, or actual encounter dates or patient identifiers.
Similar to CA SID data, we found the proportion of UCSF patients with schizophrenia who were treated 
for “disorders of muscle ligaments and fascia” to be statistically higher than expected (RA = 1.1, mean inter-
val = 296.7 ± 311.1 days, FDR < 0.1). When we tracked these data in a time-ordered manner, 98 of 3,152 
schizophrenia patients (3.1%) were hospitalized or visited the medical center for muscle disorder after the schizo-
phrenia, and 17 of those 98 (17.3%) were enriched with rhabdomyolysis (P-value of hypergeometric test 9.9E-22) 
(Fig. 3b). In UCSF, the number of rhabdomyolysis patients was 541 among 836,461 patients (0.06%). Thus, in the 
UCSF Medical Center, the diagnosis of rhabdomyolysis is also peculiarly high among schizophrenia-diagnosed 
patients (0.53%, 17 of 3152, RR = 18.3 [13.4–25.0, CI = 0.95] P-value of RR = 2.2E-16). A similar pattern was 
captured among 1,085 schizophrenia inpatients of the UCSF Medical Center (P-value of enrichment using hyper-
geometric test 1.51E-11) (Fig. 3c) (1.65%, 18 of 1085, RR = 9.61 [6.8–13.4, CI = 0.95] P-value of RR = 1.1E-15). 
Although the Columbia Open Health data does not provide a way to query using temporal order, the identical 
association between schizophrenia and rhabdomyolysis was displayed in their data resource as a matched consist-
ency (log ratio of observed co-occurrences than random = 3.01)22.
In addition, the enrichment patterns of rhabdomyolysis diagnoses among the muscle disorders in schizophre-
nia are repeated across the data of UCSF EHRs and CA SID (Fig. 3d). Among 22,374 muscle disease patients in 
our UCSF data set (ICD-9-CM code ‘728’ for disorders of muscle, ligament, and fascia), only 541 (2.4%; shown as 
a white bar in Fig. 3D) had rhabdomyolysis (ICD-9-CM code ‘728.88’). However, the diagnosis fraction of rhab-
domyolysis was sevenfold higher among the overall muscle diseases in schizophrenia patients in UCSF (17.3%, 
17 of 98 muscle disease patients with schizophrenia, shown as a black bar). The black bars in Fig. 3D represent the 
proportions of patients that were diagnosed with rhabdomyolysis among patients diagnosed with both muscle 
disorder and schizophrenia. These proportions were larger than the fraction of rhabdomyolysis in overall muscle 
disorder in UCSF EHRs and CA SID, which are indicated by the white bars.
We also examined whether rhabdomyolysis occurred following schizophrenia due to the adverse effect of arip-
iprazole, a second-generation antipsychotic20; however, we could find no evidence that any of these schizophrenia 
inpatients were administrated aripiprazole within the UCSF Medical Center. Other antipsychotic drugs, includ-
ing haloperidol and clozapine, have less clear association with rhabdomyolysis (P-value of odds ratio > 0.05); we 
believe the association between schizophrenia and rhabdomyolysis in UCSF is, thus, independent of adverse drug 
effects.
The diagnosis codes for rhabdomyolysis, often assigned for billing purposes, were also validated based on clin-
ical evidence (lab values). The levels of creatine kinase (CK) for the diagnostic confirmation of rhabdomyolysis 
greatly exceeded the normal reference (Fig. 3e) (normal reference of CK = 38–174 U/L (reference for male, blue 
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line in Fig. 3e); 96–140 U/L (reference for female, red line in Fig. 3e)) in schizophrenia–rhabdomyolysis patients 
(mean = 13847.0 ± 12192.1 U/L), which allowed a high confidence in the correct diagnoses of rhabdomyolysis 
occurrence in patients with schizophrenia (14 of 17 patients in Fig. 3b).
Although mild increases of CK levels are known to be relevant to muscle pain, metabolic abnormality, and 
drug overdose, only rhabdomyolysis is associated with extremely high CK values(10,000–200,000 U/L), due to 
the severe muscle disruption, which later can lead to renal failure23. To confirm a diagnosis of the condition, 
physicians have used the CK level test for patients who having relevant symptoms. In our previous work, we con-
firmed that the examination of CK levels are rarely ordered in among healthy individuals24, which suggests that 
CK levels are likely examined only for individuals having some prior probability of a muscle relevant symptom. 
As we expected, in the compared control group, slight elevations in CK levels among schizophrenia patients 
Fig. 3 The identified novel association between schizophrenia and rhabdomyolysis. Our scaled analysis 
of digitalized medical records from millions of patients reveals a novel association between schizophrenia 
and rhabdomyolysis. (a) DAG of schizophrenia and disorders of muscle, ligament, and fascia enriched with 
rhabdomyolysis based on the data of CA SID. (b) DAG of schizophrenia and disorders of muscle, ligament, and 
fascia enriched with rhabdomyolysis based on the EHRs of the UCSF Medical Center. (c) The identical DAG of 
(b) using the subset of the EHRs of the UCSF Medical Center consisting of inpatient records. (d) The proportion 
of the diagnoses of rhabdomyolysis in schizophrenia across different data sets. Black bars indicate the fraction 
of rhabdomyolysis among the muscle disease (ICD-9-CM code = 728) in schizophrenia. White bars represent 
the rate of rhabdomyolysis in muscle disease-diagnosed patients. (e) Lab test evidence for the diagnoses of 
rhabdomyolysis in (B). The levels of creatine kinase in patients who were diagnosed with rhabdomyolysis 
after schizophrenia are extremely high. (f) The level of creatine kinase in patients who were diagnosed with 
schizophrenia, but not diagnosed with rhabdomyolysis in (b). Because those patients already suffer with illness, 
the creatine kinase levels are mildly increased but these values are far from those of (f). The blue and red lines 
are the reference range for normal levels of creatine kinase (38–174 units/L [reference for male, blue line]; 
96–140 units/L [reference for female, red line]). The colors of dots indicate normality or abnormality marks 
assigned by healthcare providers (black for normal and orange for abnormal tags).
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without rhabdomyolysis are observed in the EHR data of UCSF (Fig. 3f, mean = 397.6 ± 768 U/L). Indeed, sim-
ply requesting a CK level itself is suggestive that there is an elevation. The control patients at UCSF are probably 
enriched with a skewed higher distribution of CK levels. However, mechanistic support for the proper diagnosis 
of rhabdomyolysis in these patients is still clear from the strikingly high CK level.
We then proceeded to conduct detailed case reviews, after obtaining approval from the UCSF Institutional 
Review Board (approval number 17-22258). We gathered the data from 29 cases in which rhabdomyolysis was 
diagnosed after schizophrenia. A case review of physicians’ notes (conducted by professional medical providers, 
including help from psychiatry) for patients with schizophrenia treated for rhabdomyolysis at UCSF between 
2011 and 2018 (n = 29) revealed that 37% of these cases (n = 11) involved illicit drug ingestions, and 13% (n = 4) 
were also from fractures/falls. Other muscle symptoms in schizophrenia that can be relevant to rhabdomyoly-
sis, such as neuroleptic malignant syndrome (NMS), catatonic seizure and spasm, were not detected from the 
healthcare records including physicians’ notes on these subsets of schizophrenia patients who were diagnosed 
with rhabdomyolysis at UCSF25. However, over half were of idiopathic origin (n = 18, 62%), and had no clinically 
known cause, including any known direct adverse effect of a medication. This suggests that rhabdomyolysis could 
be an unexpected comorbidity for schizophrenia patients. Due the low background incidence of rhabdomyolysis, 
it is possible that even more schizophrenia patients have rhabdomyolysis than recognized. If this association 
continues to be validated, psychiatrists could be counselled to consider a higher probability for rhabdomyolysis 
in schizophrenia patients.
Discussion
From the population-scale analysis of digital health records, the unexpected propensity of rhabdomyolysis to 
occur in patients with schizophrenia (0.5–2.5%) was consistently detected compared with random and sporadic 
chances across the two data sets composed of tens of millions of individuals (CA SID and UCSF EHRs, RRs 2.21–
18.35). Known possible risk factors for rhabdomyolysis, such as adverse effects of medication and neuroleptic 
malignant syndrome (NMS), were not reported in the majority of rhabdomyolysis cases following schizophrenia. 
Thus, our state-level scaled analysis of digitalized medical records from millions of patients reveals a novel asso-
ciation between schizophrenia and rhabdomyolysis.
This study included an extensive temporal analysis of disease occurrences across the discharge records of 
10.4 million patients in Californian hospitals. In total, we identified 300 serial readmissions for diverse disease 
diagnoses beginning with 118 disease nodes in 311,309 patients. Throughout 175,556 succeeding admissions 
with temporally correlated diagnosis from previous admissions and a relevant diagnosis, our approach presents 
time-aligned patterns of readmission and consistently modeled clinical associations, such as heart failure follow-
ing acute myocardial infarction, and sepsis in cancer patients26. Details of all modeled trajectories are described 
in Appendix Data S1 (and at https://github.com/hypaik/HCUPSIDCA_trajectory_tracking).
Interestingly, from the modeled disease trajectories, we repeatedly identified a novel association of diseases, 
including rhabdomyolysis following schizophrenia, from the independent data set including UCSF EHR. By com-
bining multilevel validation and case reviews of these patients with professional medical providers, an unexpected 
risk of rhabdomyolysis in schizophrenia was revealed. This finding constitutes direct evidence for the value of 
digital health records for patient care in influencing clinical practice in a systematic fashion, such as identifying 
the risk of further disease.
It is known that patients with schizophrenia and other serious psychoses are underdiagnosed and under-
treated for comorbid illnesses, such as hypertension and diabetes27. Thus, given the absence of the observational 
data recapitulation and time-ordered presentation, the association with rhabdomyolysis would have been over-
looked. Potential etiologies include drug associations because patients with schizophrenia are often treated with 
antipsychotic medications, and there is a known relationship between second-generation antipsychotics causing 
NMS, a disease of catatonia and muscle spasm that can lead to muscle breakdown. There have also been rare case 
reports of second-generation antipsychotic use in patients with schizophrenia causing rhabdomyolysis in the 
absence of NMS. Patients with schizophrenia are more vulnerable to socioeconomic stressors, such as illicit sub-
stance use and homelessness, which are all independent risk factors for rhabdomyolysis. Although these explana-
tions are still more likely, there could also be biological explanations. There are known brain disorders, including 
schizophrenia, that share genetic etiologies with diverse diseases28. Indeed, over 108 genetic loci are associated 
with schizophrenia29. It is possible that an underlying genetic predisposition can affect both neurons and muscle 
cells. For example, AHI1 is associated with both schizophrenia and metabolic abnormalities of muscles30,31 and 
perhaps could contribute to these two disease predispositions.
Several limitations of the study should be noted. Other diverse and overlooked clinical and patient features 
are invisible in our data, such as neglected symptoms including mild muscle spasm, and unreported behaviors 
relevant to rhabdomyolysis after the discharge of patients. For example, deaths occurring at home are truncated 
in our data set32. In further studies, finer acquisition of EHRs for the computational approaches, such as natural 
language processing of the chart records, will help in the care of schizophrenia patients and facilitate risk assess-
ment for rhabdomyolysis. Moreover, our trajectory model traced re-admissions within one-year. More longitu-
dinal re-admission pattern would be helpful for long-term care of patients in further studies. However, based on 
our findings, the awareness of this rare but critical risk (i.e., rhabdomyolysis) in schizophrenia patients may be 
helpful for providing adequate clinical practice. Further studies on the shared mechanistic or biological etiologies 
between schizophrenia and rhabdomyolysis should be conducted.
Two key messages can be deduced from this study. First, the analysis of health records can aid in advancing 
clinical knowledge for patient care. While most physicians are eager to comply with the latest evidence guiding 
clinical practice, scientific inquiries have been slow to uptake the rapidly expanding amount of data that are avail-
able from clinics. By using advanced data-mining analytics, we demonstrate how large-scale digital healthcare 
data can be used to facilitate the generation of medical knowledge. Second, the validation of the novel association 
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between schizophrenia and rhabdomyolysis from the large-scale analytics depends mainly on the multilevel evi-
dence of health records including finer validation of EHRs using lab test results and chart review with clinicians. 
Thus, for the specific contribution of big-data analytics and to effectively draw beneficial inference from clinical 
practice, communication with data scientists and physicians who have insight from routine clinical practice is 
indispensable. Although disease registries including CA SID are useful resources for observational studies, the 
use of a diverse range of evidence from clinical records, such as EHRs, are essential for novel findings. In this 
report, we have focused on a single example of our large-scale analysis (rhabdomyolysis after schizophrenia). 
To disseminate our findings, all our results are available on an interactive website where the mapped associa-
tions of diseases can be explored via dynamic visualization. Appendix Movie S1 (Dynamic presentation of the 
traced diagnosis trajectories at scale; https://www.youtube.com/watch?v=jJMds31-e2g) and Appendix Data S1 
(All traced diagnosis trajectories; https://github.com/hypaik/HCUPSIDCA_trajectory_tracking) presents a pre-
view of the website (http://52.89.56.137:3000/#/intro, optimized for Chrome).
By tracking millions of healthcare records, this study has revealed a novel and consistent propensity for schiz-
ophrenia patients to develop rhabdomyolysis. Digital health data are a promising resource that can be used to 
create observational evidence for clinical questions, such as readmission for relevant diseases, and to identify 
novel risk of disease patients, which can influence clinical practice. Together, these findings demonstrate the 
power of using new analytic methods on large disease registries to understand disease and mortality risk factors, 
particularly for rare but preventable diseases or outcomes.
Methods
California administrative healthcare records dataset. We used the HCUP CA SID from the AHRQ. 
This database contains deidentified admission and discharge billing information from over 350 community hos-
pitals in California, including nonfederal, general, specialty, and academic medical centers. The CA SID excludes 
non-community hospitals, such as federal hospitals (e.g., Veterans Affairs), long-term care hospitals, and clinical 
units within institutions (e.g., prisons).
We utilized five of the most recent annual builds of CA SID, which included 364 hospitals in edition 2006 
(longitudinal inpatient records between 1980–2006), 360 hospitals in edition 2007 (records between 1988–2007), 
361 hospitals in edition 2008 (records between 1987–2008), 354 hospitals in edition 2009 (records between 1988–
2009), and 354 hospitals in edition 2010 (records between 1980–2010). We merged these five CA SID editions, 
each of which consists of over 20 years of longitudinal records for about 2 million patients. Thus, the merged CA 
SID covers inpatient records between 1980 and 2010. While each edition of CA SID used unique identifiers for 
every individual, allowing us to trace patients temporally across hospitals in a longitudinal manner, these identi-
fiers were not consistent across versions, preventing meta-mapping of the patient identifiers between editions. To 
prevent data redundancy in the merged CA SID data set, we used records of only deceased individuals and their 
hospitalization records in the 2006–2009 editions, and merged these with the most recent 2010 edition.
All diagnosis codes were reported using the ICD-9-CM and rounded to the three-digit code level15 to mini-
mize overlap and subclassification of diagnoses. For example, the three-digit ICD-9-CM code for vascular demen-
tia (F01) involves subtypes consisting of dementia with or without behavioral disturbances (F01.50 or F01.51); 
therefore, we used three-digit ICD-9-CM codes to avoid diagnosis subclassifications for vascular dementia.
Temporal disease diagnoses correlations. We used the first charted diagnosis as a primary diagnosis 
code to determine the main reason for each patient hospitalization. To determine the temporal association of 
admission diagnoses correlations, we first calculated the RA measurement of all disease pairs (Disease i – Disease 
j) that occurred within one year for each patient6. Here, we used diagnoses for the patients based on the assigned 
three-digit ICD-9-CM code. RA measures relative ratio of disease co-occurrences over incidences of compared 
disease pair. The starting point of our RA measure is the database (CA SID) containing the diagnoses that Cij led 
to all hospitalization (N) of each disease identified by an ICD-9-CM code. We denote the incidence of disease i 
with Ii, and the number of patients who were diagnosed with diseases i and j with Cij. The co-occurrence value, 
between diseases can be quantified as RA = Cij/Cij*, where Cij* = Ii • Ij/N is the random expectation value of Cij. 
The statistical significance of disease comorbidities were determined by using the binomial test based on a previ-
ous study7. We selected pairs where RA was greater than one, which indicated that the co-occurrence of the two 
diseases was higher than expected by chance. Then, by modifying a previous method, we determined the likeli-
hood within a pair of diseases for one disease to occur before the other ( i jδ→  for disease i → disease j) by using the 
dates of admissions associated with the two diseases in each patient4. To calculate δ→i j, we compared diagnoses 
dated for each patient. We defined d { 1, 1}i j
p ∈ −→  as 1 if disease i was diagnosed before disease j in patient p and 
−1 otherwise. Multiple rediagnoses or rehospitalizations for the same diseases in the same patient were ignored 
and only the initial date of admission for a disease was used as a date of diagnosis for the disease. In addition, we 
only counted →di j
p  when the time between two admission dates was less than one year to filter out cases in which 
the diagnosis happened over a very long-term duration. A value of →di j
p  > 0 indicates the following: an initial 
admission for disease i occurred before the first admission for disease j in a patient p within one year. Then, the 
value of δ→i j was determined by the mean value of di j
p
→  among the set of patients who were diagnosed with dis-
eases i and j within one year. Thus, a value of i jδ→  > 0 indicates that over half of the admissions for disease i 
occurred before the admissions for disease j by one year among the patients who were diagnosed with both dis-
eases. The statistical significance of disease pair co-occurrences (RA) and temporal directionality of diseases 
( i jδ→ ) were determined by using a binomial test (Benjamini–Hochberg FDR < 0.1)7. Finally, we used pairs of 
correlated diseases with time directionality whose mathematical relationships were statistically significant 
(RA > 1, FDR < 0.1; δ→i j ≠ 0, FDR < 0.1) for further analysis. We use the term ‘temporal disease correlation’ to 
describe this relationship.
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Disease trajectories (DAGs). We joined multiple temporal disease correlations by concatenating temporal 
disease correlations into three or more steps of overall disease occurrences among patients (i.e., Disease 1 → 2 
and Disease 2 → 3 to form Disease 1 → 2 → 3)7. Because our graph model only concedes a directional pair of 
temporal disease correlation, the result of concatenation is a directed acyclic graph (DAG), which means that the 
model presents a serial pattern of disease diagnoses by time without a loop (i.e., relapse of the same disease diag-
noses again). A greedy approach was used to find subsequent steps in disease paths. Disease pairs were sorted in 
descending order according to patient counts. Pairs with overlapping diagnoses were found starting from the top 
of the list, and the number of patients following the full trajectory to death was counted. The process was stopped 
when a trajectory had no patients following it.
Data validation and case review using USCF EHRs. We utilized EHRs from UCSF collected using the 
Epic system (Verona, WI) between 2011 and 2018, which includes inpatient and outpatient records for 836,461 
unique individuals. The records were deidentified and contained no direct patient identifiers, as defined in the 
Health Insurance Portability and Accountability Act (HIPAA). For the manual case review of schizophrenia and 
rhabdomyolysis patients, the analysis protocols were reviewed and approved by the UCSF Institutional Review 
Board (approval number 17-22258).
Data Availability
Inpatient records of over 10.4 million patients from California hospitals are available via material transfer 
agreement with the HCUP of the AHRQ (https://www.ahrq.gov/research/data/hcup/). The de-identified UCSF 
EHRs covering 836,461 patients who were diagnosed at UCSF between 2011–2018 are only available from UCSF 
via inter-institutional agreement, to protect the personal information of individuals.
Code Availability
The following software and source codes were used for the presented analysis and described in the main text:
1. MySQL v14.12 was used for analysis of HCUP SIDCA data. https://www.mysql.com/downloads/
2.  An in-house developed Java script was used to trace the diagnosis trajectories of over 10.2 million patients. 
The source codes are available via GitHub repository for academic researches.
https://github.com/hypaik/HCUPSIDCA_trajectory_tracking
3.  R package version 3.2, Java v1.8.0 and Python v2.7 were used for the presented statistical analysis.
https://www.r-project.org/
https://www.oracle.com/technetwork/java/javase/downloads/jdk8-downloads-2133151.html
https://www.python.org/download/releases/2.7/
4.  Cytoscape, an open source platform, was used for the network analysis of disease trajectories and figure 
preparations. https://cytoscape.org/
5. WebGL was used for the dynamic visualization of the presented disease trajectories.
https://developer.mozilla.org/en-US/docs/Web/API/WebGL_API
6.  All the traced disease trajectories for over 10.4 million patients in California, US was presented via our web 
resource.
http://52.89.56.137:3000/#/intro (Optimized only for Chrome)
7.  We also have a website and video explaining these disease trajectories. (Appendix Movie S1. Dynamic pres-
entation of the traced diagnosis trajectories at scale)
https://www.youtube.com/watch?v=jJMds31-e2g
8.  Appendix Data S1. All of traced diagnosis trajectories. (https://github.com/hypaik/HCUPSIDCA_trajectory 
_tracking).
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